{"schema_version":"secwatch.filing_event.v1","accession":"0001562762-24-000096","form_type":"8-K","ticker":"CHE","cik":"0000019584","company_name":"CHEMED CORP","filed_at":"2024-04-24T23:59:59+00:00","discovered_at":"2026-05-14T18:03:21.308547+00:00","generated_at":"2026-06-03T09:54:02.347253+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Chemed Q1 2024: Adjusted EPS $5.20 beats; VITAS EBITDA surges 67%, Roto-Rooter down 16%","bullets":["Revenue +5.2% to $589.2M; GAAP EPS $4.24 (+18.4%); Adjusted EPS $5.20 (+21.5%)","VITAS net patient revenue +14% to $354M, ADC up 10.3% to 19,665; adjusted EBITDA +67.2% to $60.7M","Roto-Rooter revenue -5.8% to $235.2M, adjusted EBITDA -15.6% to $60.7M; margin down 299bps","Acquired Covenant Health hospice assets for $85M on Apr 17; no debt, $313.4M cash; bought back 50k shares for $32.3M","Full-year 2024 adjusted EPS guidance reaffirmed at $23.30-$23.70; next update with Q2 results"],"urls":{"canonical":"https://secwatch.observer/filing/0001562762-24-000096","json":"https://secwatch.observer/filing/0001562762-24-000096.json","markdown":"https://secwatch.observer/filing/0001562762-24-000096.md","text":"https://secwatch.observer/filing/0001562762-24-000096.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/19584/000156276224000096/0001562762-24-000096-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/19584/000156276224000096/che-20240424x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-03T09:54:02.347253+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"507617e5d8456e589b7844294ca38034c3837b7e","claim":"CHEMED CORP reported first quarter ended March 31, 2024 results: revenue $589.2 million, EPS $4.24.","evidence_excerpt":"· Revenue increased 5.2% to $589.2 million · GAAP Diluted Earnings-per-Share (EPS) of $4.24, an increase of 18.4% · Adjusted Diluted EPS of $5.20, an increase of 21.5%","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/19584/000156276224000096/0001562762-24-000096-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended March 31, 2024"},{"label":"Revenue","value":"$589.2 million"},{"label":"EPS","value":"$4.24"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}